BRUSSELS, 8-6-2015 — /EuropaWire/ — InvestHorizon announced today that applications for Investment Readiness Coaching Academies and Investment Forum events taking place from July to November 2015 are now open.
The first set of events entails:
Applying companies will have the opportunity to be trained by experienced coaches and investors in order to maximise the potential to successfully raise funding. Selected companies will be offered opportunities to present their business in front of active and specialised business angels, VCs and corporate investors at the InvestmentForum events of InvestHorizon.
Interested companies should check the full list of available events and resources and choose the ones that suit them most: http://www.investhorizon.eu/events.aspx
Applying for InvestHorizon Programme and Services
Registration
Applicants can register for the Programme and services at http://www.investhorizon.eu. As part of the process applicants must submit a company profile and draft presentation together with the registration form.
About InvestHorizon
InvestHorizon, is the Investment Readiness Programme designed to increase investments made in Innovative European SMEs through Investment Readiness development and Investor sensitization. Brought forward by 10 qualified and reliable partners, InvestHorizon offers a set of services and training across Europe, to investors and entrepreneurs, from start-up to mid-cap level. The programme is dedicated to Maximising entrepreneurs’ chances of successfully obtaining funding,through training and direct access to key European investors.
For additional information about InvestHorizon, visit investhorizon.eu.
Media Contact:
Annalisa Gardella, Project Manager
Email: annalisa@e-unlimited.com – Phone: +32 (0)2 643 3691
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…